Rossé G, Kueng E, Page M G, Schauer-Vukasinovic V, Giller T, Lahm H W, Hunziker P, Schlatter D
Preclinical Research, Pharma Division, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland.
J Comb Chem. 2000 Sep-Oct;2(5):461-6. doi: 10.1021/cc000019y.
Fluorogenic substrates for assaying novel proteolytic enzymes could be rapidly identified using an easy, solid-phase combinatorial assay technology. The methodology was validated with leader peptidase of Escherichia coli using a subset of an intramolecularly quenched fluorogenic peptide library. The technique was extended toward the discovery of substrates for a new aspartic protease of pharmaceutical relevance (human napsin A). We demonstrated for the first time known to us that potent fluorogenic substrates can be discovered using extracts of cells expressing recombinant enzyme to screen the peptide library. The straightforward and rapid optimization of protease substrates greatly facilitates the drug discovery process by speeding up the development of high throughput screening assays and thus helps more effective exploitation of the enormous body of information and chemical structures emerging from genomics and combinatorial chemistry technologies.
